The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8
Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 27, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments